A new cholesterol medication is offering hope for patients at high risk of heart attack despite taking statins. The experimental daily pill, enlicitide, significantly lowered levels of LDL (“lousy”) cholesterol, a substance that contributes to plaque buildup in arteries.
Lowering LDL cholesterol is a key strategy in preventing cardiovascular disease, a leading cause of death worldwide. If approved in the United States, the oral medication could provide an alternative to currently available injectable therapies.
According to a preliminary presentation at the American Heart Association’s Scientific Sessions 2025, held November 7-10 in New Orleans, enlicitide reduced LDL cholesterol by up to 60% in individuals with a history of heart attack or stroke, or those at high risk for these events. This research suggests a potentially more convenient option for those who need further cholesterol lowering despite lifestyle changes and standard medications like statins.
The findings, presented on November 8, 2025, are from a research abstract and have not yet undergone peer review. However, updated information from the research authors indicates the promising results. A longer cardiovascular outcomes study is currently underway to determine whether enlicitide can reduce the risk of heart attack or stroke.
Enlicitide is an oral proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor, a class of drugs known to effectively lower LDL cholesterol. A phase 2 trial demonstrated the efficacy of enlicitide decanoate in reducing LDL cholesterol levels. Further research, including a randomized clinical trial comparing enlicitide to placebo, supports these initial findings. The American Heart Association notes that this could be a valuable option for patients who haven’t reached their cholesterol goals with existing treatments.
